BillionToOne, Inc.BLLNEarnings & Financial Report
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
BLLN Q3 FY2025 Key Financial Metrics
Revenue
$83.5M
Gross Profit
$58.4M
Operating Profit
$9.6M
Net Profit
$5.7M
Gross Margin
69.9%
Operating Margin
11.5%
Net Margin
6.8%
YoY Growth
117.4%
EPS
$0.10
BillionToOne, Inc. Q3 FY2025 Financial Summary
BillionToOne, Inc. reported revenue of $83.5M (up 117.4% YoY) for Q3 FY2025, with a net profit of $5.7M (up 138.3% YoY) (6.8% margin). Cost of goods sold was $25.1M, operating expenses totaled $48.8M.
Key Financial Metrics
| Total Revenue | $83.5M |
|---|---|
| Net Profit | $5.7M |
| Gross Margin | 69.9% |
| Operating Margin | 11.5% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
BillionToOne, Inc. Q3 FY2025 revenue of $83.5M breaks down across 2 segments, led by Prenatal at $74.1M (88.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Prenatal | $74.1M | 88.7% |
| Oncology | $8.7M | 10.4% |
BillionToOne, Inc. Revenue by Segment — Quarterly Trend
BillionToOne, Inc. revenue by segment across the last 3 reported quarters, showing how each business line (such as Prenatal and Oncology) has evolved quarter over quarter.
| Segment | Q3 FY2025 | Q4 FY2024 | Q3 FY2024 |
|---|---|---|---|
| Prenatal | $74.1M | $43.2M | — |
| Oncology | $8.7M | — | — |
BillionToOne, Inc. Quarterly Revenue & Net Profit History
BillionToOne, Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $83.5M | +117.4% | $5.7M | 6.8% |
| Q4 FY2024 | $45.1M | -53.1% | $-11.5M | -25.5% |
| Q3 FY2024 | $38.4M | — | $-14.9M | -38.8% |
Income Statement
| Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|
| Revenue | $38.4M | $45.1M | $83.5M |
| YoY Growth | N/A | -53.1% | 117.4% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|
| Assets | N/A | $302.1M | $327.5M |
| Liabilities | N/A | $134.3M | $147.6M |
| Equity | $-242.9M | $-251.7M | $-239.5M |
Cash Flow
| Q3 2025 | |
|---|---|
| Operating CF | $13.8M |